Abstract
Eighty years ago Drury & Szent-Gyorgyi described the actions of adenosine, AMP (adenylic acid) and ATP (pyrophosphoric or diphosphoric ester of adenylic acid) on the mammalian cardiovascular system, skeletal muscle, intestinal and urinary systems. Since then considerable insight has been gleaned on the means by which these compounds act, not least of which in the distinction between the two broad classes of their respective receptors, with their many subtypes, and the ensuing diversity in cellular consequences their activation invokes. These myriad actions are of course predicated on the release of the purines into the extracellular milieu, but, surprisingly, there is still considerable ambiguity as to how this occurs in various physiological and pathophysiological conditions. In this review we summarise the release of ATP and adenosine during seizures and cerebral ischemia and discuss mechanisms by which the purines adenosine and ATP may be released from cells in the CNS under these conditions.
Current Neuropharmacology
Title: Release of Adenosine and ATP During Ischemia and Epilepsy
Volume: 7 Issue: 3
Author(s): Nicholas Dale and Bruno G. Frenguelli
Affiliation:
Abstract: Eighty years ago Drury & Szent-Gyorgyi described the actions of adenosine, AMP (adenylic acid) and ATP (pyrophosphoric or diphosphoric ester of adenylic acid) on the mammalian cardiovascular system, skeletal muscle, intestinal and urinary systems. Since then considerable insight has been gleaned on the means by which these compounds act, not least of which in the distinction between the two broad classes of their respective receptors, with their many subtypes, and the ensuing diversity in cellular consequences their activation invokes. These myriad actions are of course predicated on the release of the purines into the extracellular milieu, but, surprisingly, there is still considerable ambiguity as to how this occurs in various physiological and pathophysiological conditions. In this review we summarise the release of ATP and adenosine during seizures and cerebral ischemia and discuss mechanisms by which the purines adenosine and ATP may be released from cells in the CNS under these conditions.
Export Options
About this article
Cite this article as:
Dale Nicholas and Frenguelli G. Bruno, Release of Adenosine and ATP During Ischemia and Epilepsy, Current Neuropharmacology 2009; 7 (3) . https://dx.doi.org/10.2174/157015909789152146
DOI https://dx.doi.org/10.2174/157015909789152146 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dangerous Liaisons: Tau Interaction with Muscarinic Receptors
Current Alzheimer Research Lamotrigine as an Effective Treatment for Behavioral Disorders
Letters in Drug Design & Discovery The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design The Potential Role of Pro-Inflammatory and Anti-Inflammatory Cytokines in Epilepsy Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Heterotrimeric G Proteins Control Diverse Pathways of Transmembrane Signaling, a Base for Drug Discovery
Mini-Reviews in Medicinal Chemistry An Emerging Antiarrhythmic Target: Late Sodium Current
Current Pharmaceutical Design Induction of Serine Racemase Expression and D-Serine Release from Microglia by Secreted Amyloid Precursor Protein (sAPP)
Current Alzheimer Research Recent Advances in Neuromyelitis Optica Spectrum Disorder: Pathogenesis, Mechanisms and Potential Treatments
Current Pharmaceutical Design GABAergic Pharmacotherapy in the Treatment of Motor Disorders of the Central Nervous System
Current Pharmaceutical Design Triterpene Derivatives as Inhibitors of Protein Involved in the Inflammatory Process: Molecules Interfering with Phospholipase A2, Cycloxygenase, and Lipoxygenase
Current Drug Targets Pathophysiology of Erectile Dysfunction
Current Drug Targets Fetal Origins of Cardiovascular Disease
Current Cardiology Reviews Old Strategies and New Perspectives in Modulating the Endocannabinoid System
Current Bioactive Compounds Integration of Pharmacogenomics and Pharmacometrics to Support Drug Development, Regulatory and Therapeutic Decisions
Current Pharmacogenomics and Personalized Medicine Antioxidant Properties of Melatonin and its Potential Action in Diseases
Current Topics in Medicinal Chemistry Semicarbazone Analogs as Anticonvulsant Agents: A Review
Central Nervous System Agents in Medicinal Chemistry Early Intervention in Psychosis: Rationale, Results and Implications for Treatment of Adolescents at Risk
Adolescent Psychiatry Susceptibility Genes for the Side Effect of Antipsychotics on Body Weight and Obesity
Current Drug Targets In Search of Novel AMPA Potentiators
Recent Patents on CNS Drug Discovery (Discontinued) Targeted Blood-to-Brain Drug Delivery – 10 Key Development Criteria
Current Pharmaceutical Biotechnology